Tags

Type your tag names separated by a space and hit enter

Long-term toxicity and quality of life up to 10 years after low-dose rate brachytherapy for prostate cancer.
BJU Int. 2012 Apr; 109(7):994-1000.BI

Abstract

OBJECTIVE

To report on the long-term toxicity outcome for patients with prostate cancer treated by low-dose rate (LDR) brachytherapy (BXT).

PATIENTS AND METHODS

The study population comprised a cohort of men treated in our centre between March 1999 and April 2004 with LDR BXT for prostate cancer who had at least 5 years of follow-up post-implant. Patients who had died or experienced biochemical failure were excluded. We contacted eligible patients and asked them to complete a questionnaire to assess current urinary, erectile and bowel function. Urinary and erectile function was compared pre- and post-treatment and outcomes were assessed by treatment modality.

RESULTS

Of the 226 LDR BXT-treated patients with >5 years of follow-up, 174 (77.0%) responded to the questionnaire. The mean International Prostate Symptom Score (IPSS) increased from 6.70 pre-BXT to 7.91 at follow-up (P = 0.003). Of the patients with mild symptoms pre-BXT (IPSS, 0-7), 64.2% retained mild symptoms at follow-up, 31.2% developed moderate symptoms (IPSS, 8-9) and 4.6% reported severe symptoms (IPSS, 20-35). A good or acceptable quality of life (QoL) secondary to urinary symptoms (IPSS QoL, 0-4) was reported by 98.0% of respondents. Of those patients potent (International Index of Erectile Function-5 ≥11) pre-BXT, 62.9% remained potent at follow-up. There were no differences in the proportion of patients who were potent when analyzed by the number of years post-implant. At follow-up, 51.7% and 45.4% of patients, respectively, had normal or mild bowel symptoms as indicated by the European Organisation for the Research and Treatment of Cancer questionnaire (QLQ-C30/PR25 scores, 4-8). Moderate bowel symptoms (QLQ-C30/PR25 scores, 9-12) were reported by 2.9% of respondents; none reported severe symptoms.

CONCLUSION

The present study shows low morbidity after LDR BXT over the long-term for a large cohort of patients.

Authors+Show Affiliations

Royal Surrey County Hospital, Department of Urology, Guildford, Surrey, UK.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

21854533

Citation

Emara, Amr M., et al. "Long-term Toxicity and Quality of Life Up to 10 Years After Low-dose Rate Brachytherapy for Prostate Cancer." BJU International, vol. 109, no. 7, 2012, pp. 994-1000.
Emara AM, Chadwick E, Nobes JP, et al. Long-term toxicity and quality of life up to 10 years after low-dose rate brachytherapy for prostate cancer. BJU Int. 2012;109(7):994-1000.
Emara, A. M., Chadwick, E., Nobes, J. P., Abdelbaky, A. M., Laing, R. W., & Langley, S. E. (2012). Long-term toxicity and quality of life up to 10 years after low-dose rate brachytherapy for prostate cancer. BJU International, 109(7), 994-1000. https://doi.org/10.1111/j.1464-410X.2011.10460.x
Emara AM, et al. Long-term Toxicity and Quality of Life Up to 10 Years After Low-dose Rate Brachytherapy for Prostate Cancer. BJU Int. 2012;109(7):994-1000. PubMed PMID: 21854533.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Long-term toxicity and quality of life up to 10 years after low-dose rate brachytherapy for prostate cancer. AU - Emara,Amr M, AU - Chadwick,Eliot, AU - Nobes,Jenny P, AU - Abdelbaky,Ather Mohamed, AU - Laing,Robert W, AU - Langley,Stephen E M, Y1 - 2011/08/19/ PY - 2011/8/23/entrez PY - 2011/8/23/pubmed PY - 2012/4/25/medline SP - 994 EP - 1000 JF - BJU international JO - BJU Int VL - 109 IS - 7 N2 - OBJECTIVE: To report on the long-term toxicity outcome for patients with prostate cancer treated by low-dose rate (LDR) brachytherapy (BXT). PATIENTS AND METHODS: The study population comprised a cohort of men treated in our centre between March 1999 and April 2004 with LDR BXT for prostate cancer who had at least 5 years of follow-up post-implant. Patients who had died or experienced biochemical failure were excluded. We contacted eligible patients and asked them to complete a questionnaire to assess current urinary, erectile and bowel function. Urinary and erectile function was compared pre- and post-treatment and outcomes were assessed by treatment modality. RESULTS: Of the 226 LDR BXT-treated patients with >5 years of follow-up, 174 (77.0%) responded to the questionnaire. The mean International Prostate Symptom Score (IPSS) increased from 6.70 pre-BXT to 7.91 at follow-up (P = 0.003). Of the patients with mild symptoms pre-BXT (IPSS, 0-7), 64.2% retained mild symptoms at follow-up, 31.2% developed moderate symptoms (IPSS, 8-9) and 4.6% reported severe symptoms (IPSS, 20-35). A good or acceptable quality of life (QoL) secondary to urinary symptoms (IPSS QoL, 0-4) was reported by 98.0% of respondents. Of those patients potent (International Index of Erectile Function-5 ≥11) pre-BXT, 62.9% remained potent at follow-up. There were no differences in the proportion of patients who were potent when analyzed by the number of years post-implant. At follow-up, 51.7% and 45.4% of patients, respectively, had normal or mild bowel symptoms as indicated by the European Organisation for the Research and Treatment of Cancer questionnaire (QLQ-C30/PR25 scores, 4-8). Moderate bowel symptoms (QLQ-C30/PR25 scores, 9-12) were reported by 2.9% of respondents; none reported severe symptoms. CONCLUSION: The present study shows low morbidity after LDR BXT over the long-term for a large cohort of patients. SN - 1464-410X UR - https://www.unboundmedicine.com/medline/citation/21854533/Long_term_toxicity_and_quality_of_life_up_to_10_years_after_low_dose_rate_brachytherapy_for_prostate_cancer_ L2 - https://doi.org/10.1111/j.1464-410X.2011.10460.x DB - PRIME DP - Unbound Medicine ER -